Currently, the characteristics that predict immunotherapy response are tumor mutational burden (TMB), the expression of immune checkpoints (i.e., PD‐L1 expression), and “hot” T‐cell inflammatory microenvironment.32, 33, 34, 35. This evidence concerns the gene CD274 and neoplasm.